DanaherDHR
DHR
About: In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Employees: 63,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
78% more first-time investments, than exits
New positions opened: 196 | Existing positions closed: 110
59% more call options, than puts
Call options by funds: $2.21B | Put options by funds: $1.4B
30% more funds holding in top 10
Funds holding in top 10: 74 [Q2] → 96 (+22) [Q3]
5% more capital invested
Capital invested by funds: $150B [Q2] → $158B (+$7.71B) [Q3]
4% more funds holding
Funds holding: 2,138 [Q2] → 2,224 (+86) [Q3]
0% less repeat investments, than reductions
Existing positions increased: 847 | Existing positions reduced: 848
2.56% less ownership
Funds ownership: 80.21% [Q2] → 77.66% (-2.56%) [Q3]
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$265
16%
upside
Avg. target
$294
29%
upside
High target
$315
38%
upside
12 analyst ratings
10 positive
83%
2 neutral
17%
0 negative
0%
B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target | 27%upside $290 | Buy Upgraded | 13 Dec 2024 |
Wolfe Research Doug Schenkel 40% 1-year accuracy 2 / 5 met price target | 25%upside $285 | Outperform Upgraded | 31 Oct 2024 |
RBC Capital Conor McNamara 26% 1-year accuracy 10 / 39 met price target | 36%upside $311 | Outperform Maintained | 23 Oct 2024 |
TD Cowen Dan Brennan 48% 1-year accuracy 14 / 29 met price target | 38%upside $315 | Buy Maintained | 23 Oct 2024 |
Stephens & Co. Jacob Johnson 47% 1-year accuracy 8 / 17 met price target | 38%upside $315 | Overweight Reiterated | 23 Oct 2024 |
Financial journalist opinion
Based on 8 articles about DHR published over the past 30 days
Positive
Morningstar
4 days ago
3 of the Best Companies to Own in 2025 and Beyond
#Morningstar #BestStockstoInvestIn #StockInvesting These companies have durable competitive advantages and generate reliable cash flows. 00:00 Introduction 00:46 Danaher DHR 01:36 Paychex PAYX 02:17 Equifax EFX I'm Susan Dziubinski with Morningstar.
Positive
Seeking Alpha
1 week ago
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "Magic Formula" and James O'Shaughnessy's methodologies to screen stocks based on earnings yield and return on total capital. Exclude overly regulated sectors like Utilities, Financials, and REITs to focus on sectors with higher growth potential and less regulatory constraints.
Positive
Benzinga
1 week ago
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Neutral
PRNewsWire
1 week ago
Danaher Announces Quarterly Dividend
WASHINGTON , Dec. 10, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.27 per share of its common stock, payable on January 31, 2025 to holders of record on December 27, 2024. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health.
Negative
Zacks Investment Research
1 week ago
Here's Why You Should Avoid Investing in Danaher Stock Right Now
DHR experiences weakness in its operations due to softness in the Life Sciences segment. Rising expenses are added concerns.
Positive
Seeking Alpha
1 week ago
Danaher: A Resilient And Solid Company With Growth Potential
Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales.
Neutral
Seeking Alpha
2 weeks ago
Danaher Corporation (DHR) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Danaher Corporation (NYSE:DHR ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 3:25 PM ET Company Participants Rainer Blair - President and CEO Conference Call Participants Vijay Kumar - Evercore ISI Vijay Kumar Great. Thanks, everyone, for joining us this afternoon.
Neutral
PRNewsWire
3 weeks ago
Danaher to Present at Evercore ISI HealthCONx Conference
WASHINGTON , Nov. 26, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Evercore ISI HealthCONx Conference in Coral Gables, Florida on Wednesday, December 4, 2024 at 3:25 p.m.
Positive
Seeking Alpha
1 month ago
Revving Up: 2 Underperforming Dividend Giants Ready To Outshine
Two high-quality dividend stocks are finally positioned for a strong rebound. After a period of underperformance, their growth potential is back in focus. These companies have adapted well to recent challenges, enhancing their strategies to boost shareholder returns. Their fundamentals are solid and undervalued. With robust dividends and renewed growth trajectories, both stocks stand ready to outperform. Ideal picks for investors seeking stability and upside potential.
Neutral
Zacks Investment Research
1 month ago
Danaher (DHR) Reliance on International Sales: What Investors Need to Know
Examine Danaher's (DHR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Charts implemented using Lightweight Charts™